Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: A phase II trial with special reference to the hemoglobin level as prognostic parameter

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 4, 2005, Pages 261-269

  Pradier, O ^a   Lederer, K ^a   Hille, A ^a   Weiss, E ^a   Christiansen, H ^a   Schmidberger, H ^a   Hess, C F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cisplatin; Hemoglobin; Non small cell lung cancer; Radiotherapy

Indexed keywords

CISPLATIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; ESOPHAGITIS; ESOPHAGUS DISEASE; FEMALE; GAMMA RADIATION; HEMATOLOGIC DISEASE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UTERUS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 13744249682     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0633-0     Document Type: Article

References (45)

1. Armstrong J, Raben A, Zelefsky M et al. (1997) Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 44:17-22
2. Atagi S, Kawahara M, Ogawara M et al. (2000) Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 30:59-64
3. Baumann M, Appold S, Petersen C, Zips D, Herrmann T (2001) Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. Lung Cancer 33 [Suppl 1]:S35-45
4. Blackstock AW, Lesser GJ, Fletcher-Steede J et al. (2001) Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:1281-1289
5. Buccheri G, Ferrigno D (1996) Therapeutic options for regionally advanced non-small cell lung cancer. Lung Cancer 14:281-300
6. Bunn PA Jr (2001) Irinotecan and platinums in the treatment of non small-cell lung cancer. Clin Lung Cancer 2 [Suppl 2]:S14-19
7. Chevalier T Le, Arriagada R, Quoix E et al. (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423
8. Choy H, DeVore RF, Hande KR et al. (2001a) Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 34:441-449
9. Choy H, Pyo H, Kim JS, MacRae R (2001b) Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. Expert Opin Pharmacother 2:963-974
10. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346
11. Crispo A, Brennan P, Jockel KH et al. (2004) The cumulative risk of lung cancer among current, ex- and never-smokers in European men. Br J Cancer 91:1280-1286
12. Daly T, Poulsen MG, Denham JW et al. (2003) The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol 68:113-122
13. Depierre A, Milleron B, Moro-Sibilot D et al. (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247-253
14. Dillman RO, Seagren SL, Propert KJ et al. (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945
15. Dunst J (2004) Erythropoietin and radiotherapy: a dangerous combination? Strahlenther Onkol 180:133-135
16. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G (2003) Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56:778-787
17. Ginsberg RJ (1995) Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer 12 [Suppl 2]:S33-40
18. Hazuka MB, Crowley JJ, Bunn PA Jr, O'Rourke M, Braun TJ, Livingston RB (1994) Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol 12:1814-1820
19. Henke M, Laszig R, Rube C et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
20. Jeremic B, Shibamoto Y (1996) Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 34:303-308
21. Jeremic B, Shibamoto Y, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458
22. Kiura K, Ueoka H, Segawa Y et al. (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795-802
23. Langer CJ, Hirsch FR, Cortes-Funes H, Sawyer ST, Thatcher N (2003) Targeted molecular mechanisms of epoetin alfa. Lung Cancer 41 [Suppl 1]:S133-145
24. MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64:37-40
25. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
26. Obermair A, Cheuk R, Horwood K et al. (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 92:903-908
27. Perez CA, Pajak TF, Rubin P et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874-1881
28. Pisch J, Moskovitz T, Esik O, Homel P, Keller S (2002) Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pathol Oncol Res 8:163-169
29. Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125:723-729
30. Rakovitch E, Tsao M, Ung Y, Pignol JP, Cheung P, Chow E (2004) Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 58:196-203
31. Rosell R, Gomez-Codina J, Camps C et al. (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158
32. Roth JA, Atkinson EN, Fossella F et al. (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21:1-6
33. Sause WT, Scott C, Taylor S et al. (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205
34. Schaake-Koning C, Bogaert W van den, Dalesio O et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530
35. Segawa Y, Ueoka H, Kiura K et al. (2000) A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 82:104-111
36. Sibley GS, Mundt AJ, Shapiro C, Jacobs R, Chen G, Weichselbaum R, Vijayakumar S (1995) The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys 33:1001-1007
37. Simon GR, Bunn PA Jr (2003) Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest 21:87-104
38. Staar S, Rudat V, Stuetzer H et al. (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171
39. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M (1999) Influence of the hypoxic sub-volume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749-754
40. Taylor NA, Liao ZX, Cox JD et al. (2004) Equivalent outcome of patients with clinical stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204-212
41. Vokes EE, Choy H (2003) Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer 41 [Suppl 1]:S115-121
42. Vokes EE, Herndon JE 2nd, Crawford J et al. (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191-4198
43. Werner-Wasik M, Scott C, Cox JD et al. (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:1475-1482
44. Wigren T (1997) Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 44:9-15
45. Yamada M, Kudoh S, Fukuda H et al. (2002) Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer 87:258-263